Moderna logged a -0.6% change during today's morning session, and is now trading at a price of $27.38 per share.
Moderna returned losses of -52.8% last year, with its stock price reaching a high of $59.73 and a low of $23.15. Over the same period, the stock underperformed the S&P 500 index by -70.0%. AThe company's 50-day average price was $26.36. Moderna, Inc., a biotechnology company, provides messenger RNA medicines in the United States, Europe, and internationally. Based in Cambridge, MA, the Large-Cap Health Care company has 5,800 full time employees. Moderna has not offered a dividend during the last year.
The Firm Has a Declining EPS Growth Trend:
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|
| Revenue (M) | $60 | $803 | $18,471 | $19,263 | $6,848 | $3,236 |
| Operating Margins | -910% | -95% | 72% | 49% | -62% | -122% |
| Net Margins | -857% | -93% | 66% | 43% | -69% | -110% |
| Net Income (M) | -$514 | -$747 | $12,202 | $8,362 | -$4,714 | -$3,561 |
| Net Interest Expense (M) | -$8 | -$6 | -$29 | -$45 | -$124 | $24 |
| Depreciation & Amort. (M) | $31 | $31 | $232 | $348 | $617 | $185 |
| Diluted Shares (M) | 331 | 381 | 431 | 416 | 382 | 384 |
| Earnings Per Share | -$1.55 | -$1.96 | $28.29 | $20.12 | -$12.33 | -$9.28 |
| EPS Growth | n/a | -26.45% | 1543.37% | -28.88% | -161.28% | 24.74% |
| Avg. Price | $18.12 | $62.5 | $247.68 | $155.92 | $99.45 | $27.54 |
| P/E Ratio | -11.69 | -31.89 | 8.17 | 7.33 | -8.07 | -2.97 |
| Free Cash Flow (M) | -$491 | $1,959 | $13,336 | $4,581 | -$3,825 | -$4,055 |
| CAPEX (M) | $32 | $68 | $284 | $400 | $707 | $1,051 |
| Current Ratio | 7.89 | 1.43 | 1.76 | 2.73 | 3.42 | 3.67 |
Moderna does not have a meaningful trailing P/E ratio since its earnings per share are negative. Its forward EPS guidance is negative too, at $-8.7. The average P/E ratio for the Health Care sector is 22.94. On the other hand, the market is undervaluing Moderna in terms of its equity because its P/B ratio is 1.13. In comparison, the sector average is 3.19. In conclusion, Moderna's impressive cash flow trend, decent P/B ratio, and reasonable use of leverage demonstrate that the company may still be fairly valued — despite its elevated earnings multiple.
Moderna Has an Average Rating of Hold:
The 20 analysts following Moderna have set target prices ranging from $15.0 to $198.0 per share, for an average of $44.25 with a hold rating. The company is trading -38.1% away from its average target price, indicating that there is an analyst consensus of strong upside potential.
Moderna has an unusually large proportion of its shares sold short because 22.5% of the company's shares are sold short. Institutions own 74.9% of the company's shares, and the insider ownership rate stands at 7.24%, suggesting a large amount of insider shareholders. The largest shareholder is Vanguard Group Inc, whose 11% stake in the company is worth $1,142,142,857.
